Evidence map›Paper›PMID 42530392›Full record

Trial reportDiabetes, obesity & metabolism2026

Feasibility of Decentralised Response-Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease.

Jelle M Beernink, Gozewijn D Laverman, Hiddo J L Heerspink

Registry-linked trialAbstract readClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06094920. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06094920 phase4completed

Optimization of Albuminuria-Lowering Therapies for Individual Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial.

Ran2024Enrolled12Registered outcomes15Posted comparisons0ConditionsAlbuminuria, Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Chronic Kidney Diseases, Chronic Kidney Disease stage3Armsempagliflozin 10 mg, Finerenone, Hem-Col Capillary Blood Collection Device, PeeSpot Urine Collection Device, Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies
Open the trial in the graph
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jelle M BeerninkDepartment of Internal Medicine/Nephrology, Ziekenhuisgroep Twente, Almelo, the Netherlands.ORCID 0000-0002-4615-9012
Gozewijn D LavermanDepartment of Internal Medicine/Nephrology, Ziekenhuisgroep Twente, Almelo, the Netherlands.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0002-3126-3730

Funding

Boehringer Ingelheim
6 · The paper itself

Abstract

aimsTo assess the feasibility of a decentralised response-guided trial and to characterise urinary albumin-to-creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). MATERIALS AND

methodsAdults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m

resultsEleven participants completed the study (mean [SD] age 69.6 [6.1] years; mean eGFR 61.1 [24.8] mL/min/1.73 m

conclusionsA decentralised response-guided trial was feasible and safe, supporting further evaluation of this approach for individualised optimisation of kidney-protective therapy in type 2 diabetes and CKD.

trial registrationClinicalTrials.gov Identifier: NCT06094920.

Indexed as

AlbuminuriaBenzhydryl CompoundsDiabetes Mellitus, Type 2Diabetic NephropathiesGlucosidesNaphthyridinesRenal Insufficiency, ChronicAgedCreatinineDrug Therapy, CombinationFeasibility StudiesFemaleGlomerular Filtration RateHumansMaleMiddle AgedBenzhydryl CompoundsCreatinineempagliflozinfinerenoneGlucosidesNaphthyridinesSodium-Glucose Transporter 2 Inhibitorsantidiabetic drugclinical trialdiabetes complicationsdiabetic nephropathySGLT2 inhibitortype 2 diabetes

Identifiers

PMID42530392
PMCPMC13538812

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.